Skip to content
Screener

Gilead Sciences GILD Total Oncology — Total revenues

Other product segments

Biktarvy
$3.77B+6.9%
Descovy
$967M+48.1%
Trodelvy
$457M+25.5%
Yescarta
$346M-12.0%
Sofosbuvir/Velpatasvir
$303M-11.4%
Genvoya
$289M-23.3%
Vemlidy
$289M+14.7%
Odefsey
$239M-19.8%
Yeztugo
$232M+1,447%
Royalty, contract and other revenues
$176M+552%
Livdelzi
$167M+114%
Symtuza - Revenue share
$138M+11.3%
Other Liver Disease
$118M-4.1%
AmBisome
$110M-14.7%
Tecartus
$70M-23.9%
Other HIV
$56M-39.1%
Other
$51M-30.1%
Veklury
$23M-81.0%

Similar metrics at other companies

McKesson logo
MCKOncology & Multispecialty — Total revenues
$14.22B+33.4%
Schrodinger logo
SDGROncology, Neurology, and Immunology Product — Total revenues
$500K-28.6%
Sonida Senior Living logo
SNDAResident revenue — Total revenues
$108.43M+36.8%
Asset Entities logo
ASSTOther revenue — Total revenues
$43K+514%
ALN
ALNYRoyalty revenue — Total revenues
$71.67M+79.3%
Hyatt Hotels logo
HContra revenue — Total revenues
-$17M-13.3%

Other financials

Income statement

See full
Revenue$7.8B+10.2%
Gross profit$6.2B+11.5%
Operating income-$10.4B-520%
Net income-$10.5B-636%
EPS (diluted)-$8.45-642%

Balance sheet

See full
Cash & equivalents$3.2B-38.2%
Total debt$26.2B+5.2%
Total equity$11.8B-39.9%
Total assets$49.4B-11.4%

Cash flow

See full
Operating cash flow$3.6B+332%
CapEx$140.0M+30.8%
Free cash flow$3.4B+377%

Valuation

See full
Market cap$163.59B+19.3%
Enterprise value$186.66B+18.9%
P/S5.4×+0.6×

Profitability

See full
Gross margin79.6%+1.1pp
Operating margin-8.2%-36.1pp
Net margin-10.6%-32.5pp
FCF margin42.5%+10.0pp

Returns & leverage

See full
Return on equity-20.6%-53.8pp
Debt / equity2.2×+1.0×
Current ratio1.3×0.0×

Where this comes from

Reported directly by Gilead Sciences in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Gilead Sciences’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:13 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000882095-26-000031
(in millions)Three Months Ended June 30, 2026 / U.S.Three Months Ended June 30, 2026 / EuropeThree Months Ended June 30, 2026 / Rest of WorldThree Months Ended June 30, 2026 / TotalThree Months Ended June 30, 2025 / U.S.Three Months Ended June 30, 2025 / EuropeThree Months Ended June 30, 2025 / Rest of WorldThree Months Ended June 30, 2025 / Total
Yescarta1321397534616215477393
Total Cell Therapy1611738341720319686485
Trodelvy30792574572249644364
Total Oncology468265140873427291131849
Other
AmBisome4475911076556129
Other(5)22821514482173
Total Other265580161527377202

Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FAQ

What is Gilead Sciences's total oncology — total revenues?
Gilead Sciences (GILD) reported total oncology — total revenues of $873M in Q2 2026.
How has Gilead Sciences's total oncology — total revenues changed year-over-year?
Gilead Sciences's total oncology — total revenues increased by 2.8% year-over-year, from $849M to $873M.
What is the long-term trend for Gilead Sciences's total oncology — total revenues?
Over 4 years (2021 to 2025), Gilead Sciences's total oncology — total revenues has grown at a 26.8% compound annual growth rate (CAGR), from $1.25B to $3.24B.
What does total oncology — total revenues mean?
This metric represents the total gross revenue generated from the sale of oncology-focused therapeutic products and treatments. It captures the financial performance of the company's cancer-related portfolio, including both established therapies and newly acquired assets. This figure is a key indicator of the company's success in diversifying its revenue streams beyond its core infectious disease business.

Ask your AI about Gilead Sciences's total oncology — total revenues.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude